Glaxo Diabetes Entry Awaits GI-262570 After Troglitazone Rejection
Executive Summary
Glaxo Wellcome's entry into the type 2 diabetes therapy market will likely await the completion of development for the anti-glycemic compound GI-262570 following the rejection of the company's re-submitted troglitazone (Romozin) application by the U.K. Medicines Control Agency.